Cargando…
Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers
Candida albicans, along with several non-albicans Candida species, comprise a prominent fungal pathogen in humans, leading to candidiasis in various organs. The global impact of candidiasis in terms of disease burden, suffering, and fatalities is alarmingly high, making it a pressing global healthca...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674196/ https://www.ncbi.nlm.nih.gov/pubmed/38005990 http://dx.doi.org/10.3390/vaccines11111658 |
_version_ | 1785140771455762432 |
---|---|
author | Kaur, Gurpreet Chawla, Sonam Kumar, Piyush Singh, Ritu |
author_facet | Kaur, Gurpreet Chawla, Sonam Kumar, Piyush Singh, Ritu |
author_sort | Kaur, Gurpreet |
collection | PubMed |
description | Candida albicans, along with several non-albicans Candida species, comprise a prominent fungal pathogen in humans, leading to candidiasis in various organs. The global impact of candidiasis in terms of disease burden, suffering, and fatalities is alarmingly high, making it a pressing global healthcare concern. Current treatment options rely on antifungal drugs such as azoles, polyenes, and echinocandins but are delimited due to the emergence of drug-resistant strains and associated adverse effects. The current review highlights the striking absence of a licensed antifungal vaccine for human use and the urgent need to shift our focus toward developing an anti-Candida vaccine. A number of factors affect the development of vaccines against fungal infections, including the host, intraspecies and interspecies antigenic variations, and hence, a lack of commercial interest. In addition, individuals with a high risk of fungal infection tend to be immunocompromised, so they are less likely to respond to inactivated or subunit whole organisms. Therefore, it is pertinent to discover newer and novel alternative strategies to develop safe and effective vaccines against fungal infections. This review article provides an overview of current vaccination strategies (live attenuated, whole-cell killed, subunit, conjugate, and oral vaccine), including their preclinical and clinical data on efficacy and safety. We also discuss the mechanisms of immune protection against candidiasis, including the role of innate and adaptive immunity and potential biomarkers of protection. Challenges, solutions, and future directions in vaccine development, namely, exploring novel adjuvants, harnessing the trained immunity, and utilizing immunoinformatics approaches for vaccine design and development, are also discussed. This review concludes with a summary of key findings, their implications for clinical practice and public health, and a call to action for continued investment in candidiasis vaccine research. |
format | Online Article Text |
id | pubmed-10674196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106741962023-10-29 Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers Kaur, Gurpreet Chawla, Sonam Kumar, Piyush Singh, Ritu Vaccines (Basel) Review Candida albicans, along with several non-albicans Candida species, comprise a prominent fungal pathogen in humans, leading to candidiasis in various organs. The global impact of candidiasis in terms of disease burden, suffering, and fatalities is alarmingly high, making it a pressing global healthcare concern. Current treatment options rely on antifungal drugs such as azoles, polyenes, and echinocandins but are delimited due to the emergence of drug-resistant strains and associated adverse effects. The current review highlights the striking absence of a licensed antifungal vaccine for human use and the urgent need to shift our focus toward developing an anti-Candida vaccine. A number of factors affect the development of vaccines against fungal infections, including the host, intraspecies and interspecies antigenic variations, and hence, a lack of commercial interest. In addition, individuals with a high risk of fungal infection tend to be immunocompromised, so they are less likely to respond to inactivated or subunit whole organisms. Therefore, it is pertinent to discover newer and novel alternative strategies to develop safe and effective vaccines against fungal infections. This review article provides an overview of current vaccination strategies (live attenuated, whole-cell killed, subunit, conjugate, and oral vaccine), including their preclinical and clinical data on efficacy and safety. We also discuss the mechanisms of immune protection against candidiasis, including the role of innate and adaptive immunity and potential biomarkers of protection. Challenges, solutions, and future directions in vaccine development, namely, exploring novel adjuvants, harnessing the trained immunity, and utilizing immunoinformatics approaches for vaccine design and development, are also discussed. This review concludes with a summary of key findings, their implications for clinical practice and public health, and a call to action for continued investment in candidiasis vaccine research. MDPI 2023-10-29 /pmc/articles/PMC10674196/ /pubmed/38005990 http://dx.doi.org/10.3390/vaccines11111658 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kaur, Gurpreet Chawla, Sonam Kumar, Piyush Singh, Ritu Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers |
title | Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers |
title_full | Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers |
title_fullStr | Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers |
title_full_unstemmed | Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers |
title_short | Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers |
title_sort | advancing vaccine strategies against candida infections: exploring new frontiers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674196/ https://www.ncbi.nlm.nih.gov/pubmed/38005990 http://dx.doi.org/10.3390/vaccines11111658 |
work_keys_str_mv | AT kaurgurpreet advancingvaccinestrategiesagainstcandidainfectionsexploringnewfrontiers AT chawlasonam advancingvaccinestrategiesagainstcandidainfectionsexploringnewfrontiers AT kumarpiyush advancingvaccinestrategiesagainstcandidainfectionsexploringnewfrontiers AT singhritu advancingvaccinestrategiesagainstcandidainfectionsexploringnewfrontiers |